title: Filgrastim post-chemotherapy mobilizes more CD34+ cells compared to its use during steady-state haemopoiesis.
authors.forename: J
authors.initials: J
authors.lastname: Perez-Oteyza
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Laraña
authors.forename: P
authors.initials: P
authors.lastname: Ramos
authors.forename: C
authors.initials: C
authors.lastname: Zamora
authors.forename: J
authors.initials: J
authors.lastname: Lopez-Jimenez
authors.forename: E
authors.initials: E
authors.lastname: Roldan
authors.forename: J
authors.initials: J
authors.lastname: Odriozola
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim